CoChat

Role of Quinones in Toxicology

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Abstract

Quinones represent a class of toxicological intermediates which can create a variety of hazardous effects in vivo, including acute cytotoxicity, immunotoxicity, and carcinogenesis. The mechanisms by which quinones cause these effects can be quite complex. Quinones are Michael acceptors, and cellular damage can occur through alkylation of crucial cellular proteins and/or DNA. Alternatively, quinones are highly redox active molecules which can redox cycle with their semiquinone radicals, leading to formation of reactive oxygen species (ROS), including superoxide, hydrogen peroxide, and ultimately the hydroxyl radical. Production of ROS can cause severe oxidative stress within cells through the formation of oxidized cellular macromolecules, including lipids, proteins, and DNA. Formation of oxidatively damaged bases such as 8-oxodeoxyguanosine has been associated with aging and carcinogenesis. Furthermore, ROS can activate a number of signaling pathways, including protein kinase C and RAS. This review explores the varied cytotoxic effects of quinones using specific examples, including quinones produced from benzene, polycyclic aromatic hydrocarbons, estrogens, and catecholamines. The evidence strongly suggests that the numerous mechanisms of quinone toxicity (i.e., alkylation vs oxidative stress) can be correlated with the known pathology of the parent compound(s).

Overview

Integrity signals

Registry

Crossref · 10.1021/tx9902082

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 203

  1. Miller E. C., 1978, Some current perspectives on chemical carcinogenesis in humans and experimental animals: presidential address. Cancer Res. 38, 1479−1496
  2. Cavalieri E. L., 1995, Central role of radical cations in metabolic activation of polycyclic aromatic hydrocarbons. Xenobiotica 25, 677−688
  3. Marnett L. J., 1995, Biochem. Soc. Symp. 61
  4. Aust S. D., 1993, Contemporary issues in toxicology: Free radicals in toxicology. Toxicol. Appl. Pharmacol. 120, 168−178
  5. Palmer H. J., 1997, Nutr. Rev., 55
  6. Shigenaga M. K., 1991, Assays for 8-hydroxy-2‘-deoxyguanosine: A biomarker of in vivo oxidative DNA damage. Free Radical Biol. Med. 10, 211−216
  7. Schlosser M. J., 1989, Metabolic activation of hydroquinone by macrophage peroxidase. Chem.-Biol. Interact. 72, 191−207
  8. Robertson M. L., 1991, Two benzene metabolites, catechol and hydroquinone, produce a synergistic induction of micronuclei and toxicity in cultured human lymphocytes. Mutat. Res. 249, 201−209
  9. Levay G., 1991, Detection of DNA adducts in HL-60 cells treated with hyroquinone and p-benzoquinone by 32P-postlabeling. Carcinogenesis 12, 1181−1186
  10. Bolton J. L., 1998, Role of quinoids in estrogen carcinogenesis. Chem. Res. Toxicol. 11, 1113−1127
  11. Monks T. J., 1997, Biological reactivity of polyphenolic glutathione conjugates. Chem. Res. Toxicol. 10, 1296−1313
  12. Wallace L., 1996, Environmental exposure to benzene: An update. Environ. Health Perspect. 104 (Suppl. 6), 1129−1136
  13. Greenburg L., 1996, Results of medical examination and clinical tests made to discover early signs of benzol poisoning in exposed workers. Environ. Health Perspect. 104 (Suppl. 6), 1129−1136
  14. Aksoy M., 1971, Br. J. Ind. Med., 28
  15. Infante P. F., 1977, Lancet, 2, 78
  16. Fiserova-Beregerova V., 1995, Advances in occupational medicine and rehabilitation: Update on benzene
  17. Snyder R., 1996, An overview of benzene metabolism. Environ. Health Perspect. 104 (Suppl. 6), 1165−1171
  18. Seaton M. J., 1994, Benzene metabolism by human liver microsomes in relation to cytochrome P450 2E1 activity. Carcinogenesis 15, 1799−1806
  19. Valentine J. L., 1996, Reduction in benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol. Appl. Pharmacol. 141, 205−213
  20. Twerdok L. E., 1992, Induction of quinone reductase and glutathione in bone marrow stromal cells by 1,2-dithiole-3-thione: efect on hydroquinone-induced cytotoxicity. Toxicol. Appl. Pharmacol. 112, 273−281
  21. Creek M. R., 1997, Tissue distribution and macromolecular binding of extremely low doses of [14C]-benzene in B6C3F1 mice. Carcinogenesis 18, 2421−2427
  22. Smith M. T., 1996, The mechanism of benzene-induced leukemia: A hypothesis and speculation on the causes of leukemia. Environ. Health Perspec. 104 (Suppl. 6), 1219−1225
  23. He H., 1999, Phorbol ester-induced mononuclear cell differentiation is blocked by the mitogen-activated protein kinase (MEK) inhibitor PD98059. Cell Growth Differ. 10, 307−315
  24. Li Y., 1999, Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen production. Biochem. Biophys. Res. Commun. 253, 295−299
  25. Li Y., 1993, DNA damage resulting from the oxidation of hydroquinone by copper: role for a Cu(II)/Cu(I) redox cycle and reactive oxygen generation. Carcinogenesis 14, 1303−1311
  26. Rothman N., 1997, Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 57, 2839−2842
  27. Morgan J. L., 1999, Proc. Natl. Acad. Sci. U.S.A. 96
  28. Smith M. T., 1999, Proc. Natl. Acad. Sci. U.S.A. 96
  29. Trush M. A., 1996, Analysis of target cell susceptibility as a basis for the development of a chemoprotective strategy against benzene-induced hematotoxicities. Environ. Health Perspect. 104 (Suppl. 6), 1227−1234
  30. Kensler T. W., 1999, Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem. Res. Toxicol. 12, 113−126
  31. Primiano T., 1998, Identification of dithiolethione-inducible gene-1 as a leukotriene B4 12-hydroxydehydrogenase: implications for chemoprevention. Carcinogenesis 19, 999−1005
  32. Conney A. H., 1982, Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer Res. 42, 4875−4917
  33. Slaga T. J., 1977, Comparison of the tumor-initiating activities of benzo[a]pyrene arene oxides and diol-epoxides. Cancer Res. 37, 4130−4133
  34. Kim K. B., 1997, Cancer Lett., 113
  35. Leadon S. A., 1988, Proc. Natl. Acad. Sci. U.S.A. 85
  36. Chakravarti D., 1995, Proc. Natl. Acad. Sci. U.S.A. 92
  37. Denissenko M. F., 1996, Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274, 430−432
  38. Sagher D., 1983, Insertion of nucleotides opposite apurinic/apyrimidinic sites in deoxyribonucleic acid during in vitro synthesis: uniqueness of adenine nucleotides. Biochemistry 22, 4518−4526
  39. Jez J. M., 1997, A new nomenclature for the aldo-keto reductase superfamily. Biochem. Pharmacol. 54, 639−647
  40. Burczynski M. E., 1999, J. Polycyclic Aromatic Compd. (in press).
  41. Smithgall T. E., 1988, J. Biol. Chem., 263
  42. Flowers-Geary L., 1995, Identification of benzo[a]pyrene-7,8-dione as an authentic metabolite of (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene in isolated rat hepatocytes. Carcinogenesis 16, 2707−2715
  43. Tsuruda L., 1999, J. Polycyclic Aromatic Compd. (in press).
  44. Murty V. S., 1992, Characterization of mercapturic acid and glutathionyl conjugates of benzo[a]pyrene-7,8-dione by two-dimensional NMR. Bioconjugate Chem. 3, 218−224
  45. Flowers-Geary L., 1993, Cytotoxicity of polycyclic aromatic hydrocarbon o-quinones in rat and human hepatoma cells. Chem. Res. Toxicol. 6, 252−260
  46. Flowers L., 1996, Disposition and biological activity of benzo[a]pyrene-7,8-dione. A genotoxic metabolite generated by dihydrodiol dehydrogenase. Biochemistry 35, 13664−13672
  47. Shou M., 1993, Reactivity of benzo[a]pyrene-7,8-dione with DNA. Evidence for the formation of deoxyguanosine adducts. Carcinogenesis 14, 475−482
  48. McCoull K. D., 1999, Synthesis and characterization of polycyclic aromatic hydrocarbon o-quinone depurinating N7-guanine adducts. Chem. Res. Toxicol. 12, 237−246
  49. Flowers L., 1997, Cu(II), Cu(I) redox cycling, and o-semiquinone anion radicals. Biochemistry 36, 8640−8648.
  50. Breen A. P., 1995, Reactions of oxyl radicals with DNA. Free Radical Biol. Med. 18, 1033−1077
  51. Cerutti P. A., 1985, Prooxidant states and tumor promotion. Science 227, 375−381
  52. Henderson B. E., 1988, Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 48, 246−253
  53. Liehr J. G., 1990, Genotoxic effects of estrogens. Mutat. Res. 238, 269−276
  54. Feigelson H. S., 1996, Estrogens and breast cancer. Carcinogenesis 17, 2279−2284
  55. Service R. F., 1998, New role for estrogen in cancer? Science 279, 1631−1633
  56. Zhu B. T., 1998, Carcinogenesis, 19, 27
  57. Roy D., 1999, DNA damage and mutations. Mutat. Res. 424, 107−115.
  58. Liehr J. G., 1983, 2-Fluoroestradiol. Separation of Estrogenicity from Carcinogenicity. Mol. Pharmacol. 23, 278−281
  59. Li J. J., 1984, Estrogen-induced tumorigenesis in hamsters: Roles for hormonal and carcinogenic activities. Arch. Toxicol. 55, 110−118
  60. Vassilopoulou-Sellin R., 1993, Estrogen replacement therapy in women at increased risk for breast cancer. Breast Cancer Res. Treat. 28, 167−177
  61. Lupulescu A., 1995, Estrogen Use and Cancer Incidence: A Review. Cancer Invest. 13, 287−295
  62. Wickelgren I., 1997, Estrogen: A new weapon against Alzheimer's. Science 276, 676−677
  63. Henderson V. W., 1997, S27−S35.
  64. Paganinihill A., 1995, Estrogen replacement therapy and stroke. Prog. Cardiovasc. Dis. 38, 223−242
  65. Grady D., 1995, Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85, 304−313
  66. Kerlan V., 1992, Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem. Pharmacol. 44, 1745−1756
  67. Suchar L. A., 1996, Effects of phenobarbital, dexamethasone, and 3-methylcholanthrene administration on the metabolism of 17β-estradiol by liver microsomes from female rats. Endocrinology 137, 663−676
  68. Spink D. C., 1998, Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19, 291−298
  69. Shimada T., 1999, Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20, 1607−1614
  70. Li J. J., 1987, Fed. Proc. 46
  71. Li S. A., 1985, Estrogen 2- and 4-hydroxylase activity, catechol estrogen formation, and implications for estrogen carcinogenesis in the hamster kidney. Cancer Res. 45, 181−185
  72. Sarabia S. F., 1997, Mechanism of cytochrome P450-catalyzed aromatic hydroxylation of estrogens. Chem. Res. Toxicol. 10, 767−771
  73. Zhang F., 1999, The major metabolite of equilin, 4-hydroxyequilin autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem. Res. Toxicol. 12, 204−213
  74. Yager J. D., 1996, Annu. Rev. Pharmacol. Toxicol., 36, 10.1146/annurev.pa.36.040196.001223 · DOI · Paper page
  75. Iverson S. L., 1996, Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. 9, 492−499
  76. Shen L., 1997, Bioreductive activation of catechol estrogen-ortho-quinones: Aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity. Carcinogenesis 18, 1093−1101
  77. Penning T. M., 1993, Chem.-Biol. Interact., 89, 34, 10.1016/0009-2797(93)03203-7 · DOI
  78. Malins D. C., 1996, Proc. Natl. Acad. Sci. U.S.A. 93
  79. Shigenaga M. K., 1991, Assays for 8-hydroxy-2‘-deoxyguanosine: A biomarker of in vivo oxidative DNA damage. Free Radical Biol. Med. 10, 211−216
  80. Floyd R. A., 1990, The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis 11, 1447−1450
  81. Han X., 1994, 8-Hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol. Role of free radicals in estrogen-induced carcinogenesis. Cancer Res. 54, 5515−5517
  82. Nutter L. M., 1994, Chem. Res. Toxicol., 7, 28
  83. Li J. J., 1993, Estrogen carcinogenesis in the hamster kidney: role of cytotoxicity and cell proliferation. Environ. Health Perspect. 5, 259−264
  84. Banerjee S. K., 1994, Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens. Mutat. Res. 311, 191−197
  85. Chen Y., 1998, The equine estrogen metabolite 4-hydroxyequilenin causes DNA single strand breaks and oxidation of DNA bases in vitro. Chem. Res. Toxicol. 11, 1105−1111
  86. Chen Y., 2000, GADD153 expression and apoptosis in breast cancer cell lines. Chem. Res. Toxicol. (submitted for publication).
  87. Han X., 1995, Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: correlation of DNA damage by free radicals with metabolic activation to quinones. Carcinogenesis 16, 2571−2574
  88. Liehr J. G., 1986, Proc. Natl. Acad. Sci. U.S.A. 83
  89. Liehr J. G., 1987, Localization of estrogen-induced DNA adducts and cytochrome P450 activity at the site of renal carcinogenesis in the hamster kidney. Cancer Res. 47, 2156−2159
  90. Abul-Hajj Y. J., 1995, J. Am. Chem. Soc., 117
  91. Stack D. E., 1996, Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem. Res. Toxicol. 9, 851−859
  92. Loeb L. A., 1986, Annu. Rev. Genet., 20
  93. Cavalieri E. L., 1997, Proc. Natl. Acad. Sci. U.S.A. 94
  94. Shen L., 1997, J. Am. Chem. Soc., 119
  95. Shen L., 1998, Chem. Res. Toxicol., 11, 101
  96. Ricaurte G., 1985, Hallucinogenic amphetamine selectively destroys serotonin nerve terminals. Science 229, 986−988
  97. Commins D. L., 1987, J. Pharmacol. Exp. Ther., 241
  98. Henry J. A., 1992, Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet 340, 384−387
  99. Stone D. M., 1986, Eur. J. Pharmacol., 128, 48
  100. Stone D. M., 1987, Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26, 1677−1683
  101. Battaglia G., 1987, J. Pharmacol. Exp. Ther., 242
  102. Lew R., 1996, J. Pharmacol. Exp. Ther., 276
  103. Bolla K. I., 1998, Memory impairmant in abstinent MDMA (“ecstasy”) users. Neurology 51, 1532−1537
  104. McCann U. D., 1999, Cognitive performance in (±)-3,4-methylenedioxyamphetamine (MDMA, “ecstasy”) users: a control study. Psychopharmacology 143, 147−425
  105. McCann U. D., 1998, Positron emission tomographic evidence of toxic effects of MDMA (“ecstasy”) on brain serotonin neurons in human beings. Lancet 352, 1433−1437
  106. Ricuarte G. A., 1988, Toxic effects of MDMA on central serotonergic neurons in primate: importance of route and frequency of drug administration. Brain Res. 446, 165−168
  107. Molliver M. E., 1986, Soc. Neurosci. Abstr., 12, 1234
  108. Schmidt C. J., 1988, Eur. J. Pharmacol., 156
  109. Paris J. M., 1992, Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain. Res. Bull. 28, 115−119
  110. Gollamudi R., 1989, Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 10, 455−466
  111. McCann U. A., 1991, Major metabolites of 3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons. Brain Res. 545, 279−282
  112. Midha K. K., 1978, α-Methyldopamine, a key intermediate in the metabolic disposition of 3,4-methylenedioxyamphetamine in vivo in dog and monkey. Drug Metab. Dispos. 6, 623−630
  113. Lim H. K., 1988, vivo and in vitro metabolism of 3,4-methylenedioxymethamphetamine in the rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1, 370−378
  114. Hiramatsu M., 1990, J. Pharmacol. Exp. Ther., 254
  115. Patel N., 1991, Transformation of dopamine and α-methyldopamine by NG-108-15 cells: formation of thiol adducts. Chem. Res. Toxicol. 4, 421−426
  116. Miller R. T., 1995, Metabolism of 5-(Glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem. Res. Toxicol. 8, 634−641
  117. Tunek A., 1981, Toxic effects of benzene and benzene metabolites on granulopoietic stem cells and bone marrow cellularity in mice. Toxicol. Appl. Pharmacol. 59, 149−156
  118. Yin S. N., 1987, Br. J. Ind. Med., 44
  119. Snyder R., 1993, Studies on the mechanism of benzene toxicity. Environ. Health Perspect. 100, 293−306
  120. Bratton S. B., 1997, Identification of quinol-thioethers in bone marrow of hydroquinone/phenol-treated rats and mice and their potential role in benzene-mediated hematotoxicity. Chem. Res. Toxicol. 10, 859−865
  121. Thompson C. B., 1995, Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456−1462
  122. Moran J. L., 1996, Induction of apoptosis by benzene metabolites in HL-60 cells and CD34+ human bone marrow progenitor cells. Mol. Pharmacol. 50, 610−615
  123. Hazel B. A., 1996, Hydroquinone, a bioreactive metabolite of benzene, inhibits apoptosis in myeloblasts. Stem Cells 14, 730−742
  124. Liu B., 1997, J. Biol. Chem., 272
  125. Hannun Y. A., 1996, Functions of ceramide in coordinating cellular responses to stress. Science 274
  126. Zager R. A., 1997, Kidney Int., 52, 70
  127. Nicholson D. W., 1995, Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis Nature 376, 37−43
  128. Dobrowski R. T., 1992, J. Biol. Chem., 267
  129. Suzuki Y. J., 1997, Oxidants as stimulators of signal transduction. Free Radical Biol. Med. 22, 269−285
  130. Rajavashisth T. B., 1990, Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344, 254−257
  131. Ishiguro S., 1976, Glass capillary column gas chromatographic analysis of tobacco and cellulose cigarette smoke. I. Acidic fractions. Kenkyu HokokuNippon Senbai Kosha Chuo Kenkyusho 118, 207−211
  132. Kari F. W., 1992, Toxicity and carcinogenicity of hydroquinone in F344/N rats and B6C3F1 mice. Food Chem. Toxicol. 30, 737−747
  133. Shibata M. A., 1991, Jpn. J. Cancer Res., 82
  134. Peters M. M., 1997, Cytotoxicity and cell proliferation induced by the nephrocarcinogen hydroquinone, and its nephrotoxic metabolite 2,3,5-tris-(glutathion-S-yl)hydroquinone. Carcinogenesis 18, 2393−2401
  135. Lau S. S., 2000, The nephrocarcinogenicity of a nephrotoxic metabolite of the “non-genotoxic
  136. Peters M. M., 1996, Metabolism of 2-tert-butylhydroquinone to S-substituted conjugates in the male Fischer 344 rat. Chem. Res. Toxicol. 9, 133−139
  137. Peters M. M., 1996, Glutathione conjugates of 2-tert-butylhydroquinone, metabolites of the renal tumor promoter tert-butylhydroxyanisole, are toxic to kidney and bladder. Cancer Res. 56, 1006−1011
  138. Tsuda H., 1984, Acta Pharmacol. Toxicol., Suppl., 2
  139. Ito N., 1986, Studies on antioxidants: their carcinogenic and modifying effects on chemical carcinogenesis. Food Chem. Toxicol. 24, 1071−1082
  140. Verhagen H., 1989, Disposition of single oral doses of butylated hydroxyansiole in man and rat. Food Chem. Toxicol. 27, 151−158
  141. Shibata M. A., 1991, Toxicol. Lett., 55
  142. Verhagen H., 1991, Butylated hydroxyanisole in perspective. Chem.-Biol. Interact. 80, 109−134
  143. Liehr J. G., 1990, Free radical generation of cycling estrogens. Free Radical Biol. Med. 8, 415−423
  144. Matthews V. S., 1947, Proc. Soc. Exp. Biol. Med. 66
  145. Kirkman H., 1952, J. Natl. Cancer Inst., 13
  146. Kirkman H., 1959, Natl. Cancer Inst. Monogr., 1, 57
  147. Hattori N., 1991, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30, 563−571.
  148. Mizuno Y., 1994, An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35, 204−210
  149. Ikebe S., 1995, Point mutations of mitochondrial genome in Parkinson's disease. Brain Res. Mol. Brain Res. 28, 281−295
  150. Swerdlow R. H., 1996, Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40, 663−671
  151. Kobayashi T., 1998, Association between the gene encoding the E2 subunit of the α-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann. Neurol. 43, 120−123
  152. Schapira A. H. V., 1996, Neurodegeneration and Neuroprotection in Parkinson's Disease
  153. Dexter D. T., 1989, J. Neurochem., 52
  154. Alam Z. I., 1997, J. Neurochem., 69
  155. Alam Z. I., 1997, J. Neurochem., 69
  156. Benzi G., 1991, Sequential damage in mitochondrial complexes by peroxidative stress. Neurochem. Res. 16, 1295−1302
  157. Dexter D. T., 1994, Ann. Neurol., 35, 44
  158. Sian J., 1994, Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348−355
  159. Sian J., 1994, Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36, 356−361
  160. Seaton T. A., 1996, Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. Biochem. Pharmacol. 52, 1657−1663
  161. Meister A., 1981, γ-Glutamyl transpeptidase. Methods Enzymol. 77, 237−253
  162. Mithofer K., 1992, Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Arch. Biochem. Biophys. 295, 132−136
  163. Khan S., 1997, Rapid and specific efflux of glutathione before hepatocyte injury induced by hypoxia. Biochem. Biophys. Res. Commun. 238, 320−322
  164. Reed D. J., 1995, Biochim. Biophys. Acta, 1271, 50
  165. Sanchez-Ramos J., 1998, Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. Exp. Neurol. 150, 263−271
  166. Seidler A., 1996, Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46, 1275−1284
  167. Fleming L., 1994, Parkinson's disease and brain levels of organochlorine pesticides. Ann. Neurol. 36, 100−103
  168. Corrigan F. M., 1998, Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp. Neurol. 150, 339−342
  169. Le Couteur D. G., 1998, The ageing liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin. Pharmacokinet. 34, 359−373
  170. Ho S. L., 1996, Adv. Neurol., 69, 60
  171. Steventon G. B., 1989, Xenobiotic metabolism in Parkinson's disease. Neurology 39, 883−887
  172. Armstrong M., 1992, Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339, 1017−1018
  173. Stroombergen M. C., 1999, Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum. Exp. Toxicol. 18, 141−145
  174. De Palma G., 1998, Case-control study of interactions between genetic and environmental factors in Parkinson's disease. Lancet 352
  175. Bandmann O., 1997, Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 350, 1136−1139
  176. Shahi G. S., 1990, Parkinson's disease and cytochrome P450: a possible link? Med. Hypotheses 32, 277−282
  177. Gerlach M., 1996, J. Neural Transm., 103
  178. Ferraro T. N., 1986, Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Neuropharmacology 25, 1071−1074
  179. Yong V. W., 1986, Neurosci. Lett., 63, 60
  180. Oishi T., 1993, Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. J. Neural Transm.: Parkinson's Dis. Dementia Sect. 6, 45−52
  181. Ramsay R. R., 1986, Energy driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 39, 581−588
  182. Mizuno Y., 1987, Inhibition of mitochondrial α-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem. Biophys. Res. Commun. 143, 971−976
  183. Smith T. S., 1994, eport 5, 2598−2600.
  184. Cao C. J., 1990, ATP-regulated neuronal catecholamine uptake: a new mechanism. Life Sci. 47, 655−667
  185. Han J., 1999, J. Neurochem., 73
  186. Dringen R., 1997, The γ-glutamyl transpeptidase inhibitor acivicin preserves glutathione released by astroglial cells in culture. Neurochem. Res. 22, 727−733
  187. Novelli A., 1988, Glutamate becomes neurotoxic when intracellular energy levels are reduced. Brain Res. 451, 205−212
  188. Zeevalk G. D., 1991, J. Pharmacol. Exp. Ther., 257
  189. Olney J. W., 1990, l-Cysteine, a bicarbonate-sensitive excitotoxin. Science 248, 596−599
  190. Lafon-Cazal M., 1993, NMDA-dependent superoxide production and neurotoxicity. Nature 364, 535−537
  191. Beal M. F., 1996, Neurodegeneration and Neuroprotection in Parkinson's Disease
  192. Beckman J. S., 1990, Proc. Natl. Acad. Sci. U.S.A. 87
  193. Flint D. H., 1993, J. Biol. Chem., 268
  194. Gutteridge J. M. C., 1996, Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Ann. N.Y. Acad. Sci. 738, 201−213
  195. Spencer J. P. E., 1998, J. Neurochem., 71
  196. Sagara J., 1993, J. Neurochem., 61
  197. Tate S. S., 1985, γ-Glutamyl transpeptidase from kidney. Methods Enzymol. 113, 400−437
  198. Zhang F., 1994, J. Med. Chem., 37
  199. Shen X.-M., 1996, Further insights into the influence of l-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 751−763
  200. Li H., 1997, J. Neurochem., 69

200 of 203 shown

Cited by

See all 1,703

Metadata

Authors
Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., & Monks, T. J.
Affiliations
Johns Hopkins University (US)
Venue
Chemical Research in Toxicology
Published
2000-02-23
Volume
13
Issue
3
Pages
135-160
ISSN
  • 0893-228X (ISSN-L)
  • 1520-5010
OpenAlex
W2090990681
Cited by
1,703
References
96
Citations by year
2026: 61 · 2025: 55 · 2024: 51 · 2023: 66 · 2022: 65 · 2021: 82 · 2020: 68 · 2019: 76 · 2018: 71 · 2017: 63 · 2016: 75 · 2015: 80 · 2014: 89 · 2013: 79 · 2012: 78
FWCI
6.33
Type
journal article
Language
en
Open access
closed
Locations
  • Chemical Research in Toxicology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01es003760-16)
  • National Cancer Institute (CA73638)
  • National Institute of Environmental Health Sciences (ES03760, ES03819, P30ES003819)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Carcinogens and Genotoxicity Assessment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
Keywords
quinones, quinone toxicity, Michael acceptors, alkylation, redox cycling, semiquinone, reactive oxygen species, oxidative stress, 8-hydroxy-2'-deoxyguanosine, carcinogenesis, immunotoxicity, cytotoxicity, benzene, polycyclic aromatic hydrocarbons, estrogen metabolites, catecholamines, protein kinase C, Ras signaling
MeSH terms
Alkylation, Animals, Benzene, Catecholamines, Estrogens, Humans, Polycyclic Aromatic Hydrocarbons, Quinones, Oxidative Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.